Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with Induction Chemotherapy for Hypopharyngeal Carcinoma
NCT04156698Phase 2Active, not recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- May 2020
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in hypopharyngeal squamous cell carcinoma (HSCC), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoint: Overall Response Rate at 9 weeks. Started May 2020; status: active, not recruiting.
02
Drugs
camrelizumab
03
Conditions
hypopharyngeal squamous cell carcinoma (HSCC)
Beyond the preview
Go deeper on NCT04156698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04156698.